ClinicalTrials.gg
CompletedNCT01789606Updated Aug 28, 2017Results posted

Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet

A Phase 3 interventional study of Ibuprofen 600 mg Immediate Release/Extended Release Caplet in Analgesia, sponsored by Pfizer. Completed at 18 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,083
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.

02

Conditions studied

  • Analgesia

Keywords

  • Self-selection and actual use/compliance trial.
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 12 years of age
  • use of at least 5 doses per month of over-the-counter pain relievers over the past 3 months
  • provide written (subjects 12-\<18 years of age provide a written assent and parent/guardian will provide written informed consent)
  • capable of and willing to swallow the study medication

Exclusion criteria

Exclusion Criteria:

  • participated in other research studies in the last 6 months
  • they or someone else in their household work for a pharmaceutical company, is a relative of study site personnel involved with the study, or an immediate family member is already enrolled in the study
  • have a history of known allergies to ibuprofen, aspirin, or other NSAIDs
  • have a history of heart surgery in the last 60 days or planned heart surgery in the next 60 days
  • female subjects are pregnant or breast feeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,083 participants (actual)

Study arms

  • Experimental
    Ibuprofen 600 mg Immediate Release/Extended Release Caplet

    Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Interventions

  • DrugIbuprofen 600 mg Immediate Release/Extended Release Caplet

    Drug page: Ibuprofen

    Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication

    Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.

    Time frame: Day 1

  2. Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity

    Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of \<6 hours, if left untreated. Participants were classified as "missed opportunity" cases when they selected the Ibuprofen 200 mg IR medication with their typical duration of pain \>=6 hours.

    Time frame: Day 1

  3. Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours

    Percentage of participants with correct selection of Ibuprofen 600 mg IR/ER medication with a typical duration of pain \<6 hours were reported in this outcome measure.

    Time frame: Day 1

  4. Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours

    Percentage of participants with selection of Ibuprofen 200 mg IR medication with a typical duration of pain \>=6 hours were reported in this outcome measure. These participants were classified as ''missed opportunity'' cases.

    Time frame: Day 1

  5. Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg

    Percentage of participants with the use of study medication for \>10 days with an average daily dose of \>1600 mg were reported in this outcome measure.

    Time frame: Day 1 up to Day 30

  6. Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg

    Percentage of participants who used the study medication for \<=10 days and used more than 20 tablets with an average daily dose of \>1600 mg were reported in this outcome measure.

    Time frame: Day 1 up to Day 30

Secondary outcomes

  1. Average Daily Dose Among Excessive Users

    Excessive users included all participants who used the study medication for more than 10 days (not necessarily consecutive) during study period with an average daily dose of \>1600 mg or all participants who used the study medication for \<=10 days during study period, used more than 20 tablets and had an average daily dose of \>1600 mg.

    Time frame: Day 1 up to Day 30

  2. Number of Dosing Days Among Inappropriate Users

    Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, if left untreated, based on the information provided at the follow up interview.

    Time frame: Day 1 up to Day 30

  3. Number of Pain Episodes Treated With Single Dose or Multiple Dose Among Inappropriate Users

    In this outcome measure, number of pain episodes treated with single dose or multiple dose per day among inappropriate users were reported. Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, based on the information provided at the follow up interview.

    Time frame: Day 1 up to Day 30

  4. Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram

    Number of treatment days when participants exceeded the daily dose of 1200 milligram were reported in this outcome measure.

    Time frame: Day 1 up to Day 30

  5. Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms

    In this outcome measure, number of treatment days exceeding the daily dose of 1200 mg, excluding the days when severe symptoms were treated, were reported.

    Time frame: Day 1 up to Day 30

  6. Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram

    In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg were reported.

    Time frame: Day 1 up to Day 30

  7. Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms

    In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg, excluding the events when severe symptoms were treated, were reported.

    Time frame: Day 1 up to Day 30

  8. Average Daily Dose of Study Medication

    Time frame: Day 1 up to Day 30

  9. Maximum Daily Dose of Study Medication

    Time frame: Day 1 up to Day 30

07

Results

Posted Aug 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneSelf-Selection ArmCompliance Arm
Started251832
Completed228382
Not completed23450
Withdrew: Participant not purchased the product020
Withdrew: Withdrawal by subject01
Withdrew: Ineligible62
Withdrew: Administrative reasons176
Withdrew: No study medication taken01
Withdrew: Protocol violation055
Withdrew: Adverse event03
Withdrew: Lost to follow-up014
Withdrew: Ineligible or not willing to continue0348

Outcome measures

PrimaryPercentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication

Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of less than (\<) 6 hours, if left untreated.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication
percentage of participantsSelf-Selection Arm
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER) Study Medication69.1 (63.3 to 74.8)
PrimaryPercentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity

Participants as correct selectors included all participants who selected Ibuprofen 600 mg IR/ER medication with the last episode of pain of \>=6 hours, if left untreated. Participants as correct de-selectors included all participants who either selected Ibuprofen 200 mg or selected 'neither' with a typical pain duration of \<6 hours, if left untreated. Participants were classified as "missed opportunity" cases when they selected the Ibuprofen 200 mg IR medication with their typical duration of pain \>=6 hours.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity
percentage of participantsSelf-Selection Arm
Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 mg IR/ER Study Medication Excluding Those Classified as Missed Opportunity82.7 (77.6 to 87.8)
PrimaryPercentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours

Percentage of participants with correct selection of Ibuprofen 600 mg IR/ER medication with a typical duration of pain \<6 hours were reported in this outcome measure.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours
percentage of participantsSelf-Selection Arm
Percentage of Participants Who Select to Use Ibuprofen 600 mg IR/ER Medication With a Typical Pain Duration of Less Than (<) 6 Hours63.2 (47.8 to 78.5)
PrimaryPercentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours

Percentage of participants with selection of Ibuprofen 200 mg IR medication with a typical duration of pain \>=6 hours were reported in this outcome measure. These participants were classified as ''missed opportunity'' cases.

Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours
percentage of participantsSelf-Selection Arm
Percentage of Participants Who Select to Use Ibuprofen 200 mg IR Medication With a Typical Pain Duration of Greater Than or Equal to (>=) 6 Hours20.9 (15.4 to 26.3)
PrimaryPercentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg

Percentage of participants with the use of study medication for \>10 days with an average daily dose of \>1600 mg were reported in this outcome measure.

Time frame:
Day 1 up to Day 30
Reported as:
Number · percentage of participants
Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg
percentage of participantsCompliance Arm
Percentage of Participants With the Use of Study Medication For Greater Than (>) 10 Days With an Average Daily Dose of Greater Than (>) 1600 mg1.2 (0.2 to 2.3)
PrimaryPercentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg

Percentage of participants who used the study medication for \<=10 days and used more than 20 tablets with an average daily dose of \>1600 mg were reported in this outcome measure.

Time frame:
Day 1 up to Day 30
Reported as:
Number · percentage of participants
Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg
percentage of participantsCompliance Arm
Percentage of Participants With the Use of Study Medication For Less Than or Equal to (<=) 10 Days and Use More Than 20 Tablets With an Average Daily Dose of Greater Than (>) 1600 mg0 (0 to 0)
SecondaryAverage Daily Dose Among Excessive Users

Excessive users included all participants who used the study medication for more than 10 days (not necessarily consecutive) during study period with an average daily dose of \>1600 mg or all participants who used the study medication for \<=10 days during study period, used more than 20 tablets and had an average daily dose of \>1600 mg.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · milligram
Average Daily Dose Among Excessive Users
milligramCompliance Arm
Average Daily Dose Among Excessive Users1821.1 ± 157.4
SecondaryNumber of Dosing Days Among Inappropriate Users

Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, if left untreated, based on the information provided at the follow up interview.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · days
Number of Dosing Days Among Inappropriate Users
daysCompliance Arm
Number of Dosing Days Among Inappropriate Users14.8 ± 8.1
SecondaryNumber of Pain Episodes Treated With Single Dose or Multiple Dose Among Inappropriate Users

In this outcome measure, number of pain episodes treated with single dose or multiple dose per day among inappropriate users were reported. Participants were considered as inappropriate users if they improperly used the study medication in their last pain episode duration of \<6 hours, based on the information provided at the follow up interview.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · pain episodes
Number of Pain Episodes Treated With Single Dose or Multiple Dose Among Inappropriate Users
pain episodesCompliance Arm
Single dose13.1 ± 7.4
Multiple dose1.8 ± 2.6
SecondaryNumber of Treatment Days Exceeding the Daily Dose of 1200 Milligram

Number of treatment days when participants exceeded the daily dose of 1200 milligram were reported in this outcome measure.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · days
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram
daysCompliance Arm
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram0.31 ± 1.188
SecondaryNumber of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms

In this outcome measure, number of treatment days exceeding the daily dose of 1200 mg, excluding the days when severe symptoms were treated, were reported.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · days
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms
daysCompliance Arm
Number of Treatment Days Exceeding the Daily Dose of 1200 Milligram Excluding Treatment of Severe Symptoms0.12 ± 0.637
SecondaryNumber of Dosing Occasions Exceeding the Single Dose of 600 Milligram

In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg were reported.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · dosing occasions
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram
dosing occasionsCompliance Arm
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram1.48 ± 4.185
SecondaryNumber of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms

In this outcome measure, number of dosing occasions exceeding the single dose of 600 mg, excluding the events when severe symptoms were treated, were reported.

Time frame:
Day 1 up to Day 30
Reported as:
Mean · dosing occasions
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms
dosing occasionsCompliance Arm
Number of Dosing Occasions Exceeding the Single Dose of 600 Milligram Excluding Treatment of Severe Symptoms0.83 ± 3.020
SecondaryAverage Daily Dose of Study Medication
Time frame:
Day 1 up to Day 30
Reported as:
Mean · milligram
Average Daily Dose of Study Medication
milligramCompliance Arm
Average Daily Dose of Study Medication781.0 ± 229.3
SecondaryMaximum Daily Dose of Study Medication
Time frame:
Day 1 up to Day 30
Reported as:
Mean · milligram
Maximum Daily Dose of Study Medication
milligramCompliance Arm
Maximum Daily Dose of Study Medication1147.9 ± 604.43

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Compliance Arm—1/405 (0.2%)163/405 (40.2%)
Most frequent serious events
Most frequent serious events
EventCompliance Arm
Pleural infectionInfections and infestations1/405
Most frequent other events
Showing 10 of 59
Most frequent other events
EventCompliance Arm
NasopharyngitisInfections and infestations59/405
ToothacheGastrointestinal disorders26/405
Back painMusculoskeletal and connective tissue disorders15/405
MyalgiaMusculoskeletal and connective tissue disorders12/405
HeadacheNervous system disorders10/405
Abdominal pain upperGastrointestinal disorders6/405
SinusitisInfections and infestations6/405
Ligament sprainInjury, poisoning and procedural complications6/405
ArthralgiaMusculoskeletal and connective tissue disorders6/405
Tension headacheNervous system disorders6/405

Baseline characteristics

Analysis population included all the participants who were randomized in the study.

Age, Customized
Age, Customized(participants)Self-Selection ArmCompliance ArmTotal
Less Than (<)18 years257
Greater Than or Equal to (>=) 18 years2478271074
Unknown202
Sex/Gender, Customized
Sex/Gender, Customized(participants)Self-Selection ArmCompliance ArmTotal
Female114408522
Male114403517
Unknown232144
08

Study locations

18 sites
  • Medical Arts Rexall Pharmacy
    Anaheim, California 92801, United States
  • B and B Pharmacy
    Yorba Linda, California 92886, United States
  • Wynn's Pharmacy Inc.
    Griffin, Georgia 30224, United States
  • Stark Pharmacy
    Overland Park, Kansas 66209, United States
  • Catonsville Pharmacy
    Baltimore, Maryland 21228, United States
  • Goodrich Pharmacy
    Blaine, Minnesota 55434, United States
  • Kemper Drug
    Elk River, Minnesota 55330, United States
  • Cub Pharmacy Number 1924
    Saint Louis Park, Minnesota 55426, United States
  • Albers' Medical Pharmacy
    Kansas City, Missouri 64111, United States
  • Countryside Pharmacy
    Savannah, Missouri 64485, United States
  • Duran Central Pharmacy
    Albuquerque, New Mexico 87104, United States
  • Total Health and Wellness Center of Taos
    Taos, New Mexico 87571, United States
  • The Medicine Shoppe
    Ogden, Utah 84401, United States
  • The Medicine Shoppe
    Salt Lake City, Utah 84121, United States
  • Family Plaza Pharmacy
    West Jordan, Utah 84088, United States
  • Montpelier Pharmacy, Inc.
    Montpelier, Virginia 23192, United States
  • Ostrom Drugs
    Kenmore, Washington 98028, United States
  • Kusler's Pharmacy
    Snohomish, Washington 98290, United States
09

References and documents

Publications

  • Paluch E, Jayawardena S, Wilson B, Farnsworth S. Consumer self-selection, safety, and compliance with a novel over-the-counter ibuprofen 600-mg immediate-release and extended-release tablet. J Am Pharm Assoc (2003). 2016 Jul-Aug;56(4):397-404. doi: 10.1016/j.japh.2016.03.003. Epub 2016 May 13. PubMed 27184785 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2012 to primary completion in Jun 2013, 8 months.

Results were first posted in Aug 2017, 4 years 2 months after primary completion. A results delay was requested in Jul 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2012
First posted
Feb 12, 2013
StartActual
Sep 24, 2012
Primary completionActual
Jun 3, 2013
CompletionActual
Jun 3, 2013
Results delay requested
Jul 25, 2014
Results first posted
Aug 28, 2017
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01789606
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 12, 2013
Start date
Sep 24, 2012
Primary completion
Jun 3, 2013
Completion
Jun 3, 2013
Results posted
Aug 28, 2017
Last update
Aug 28, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion